Is ABCL a Buy? What to Consider in 2026
Short answer
The bull case for AbCellera Biologics (ABCL) rests on Own-pipeline catalysts in 2026: AbCellera has two internal candidates in the clinic with near-term readouts: ABCL-635 (a potential first-in-class NK3R antibody for menopausal hot flashes) with top-line Phase 2 data guided to Q3 2026, and ABCL-575 for atopic dermatitis with Phase 1 top-line data expected in Q4 2026. Revenue (Q1 2026) is ~$8.3M (up from ~$4.2M yr-ago). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: AbCellera is unprofitable and burning cash, posting a net loss of roughly $43M in Q1 2026 against only about $8M of quarterly revenue, so the market value rests on future clinical success rather than current earnings. Whether ABCL is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
AbCellera Biologics (Nasdaq: ABCL) built an AI-assisted, single-cell antibody-discovery platform (spun out of the University of British Columbia) that it originally rented to pharma partners such as Eli Lilly, Regeneron, AbbVie and Biogen in exchange for research fees, milestones and downstream royalties. Since 2023 it has deliberately scaled back partnership volume to redirect resources into its own internal pipeline, marking a shift from a services-and-royalties model toward being a clinical-stage drug developer that captures more of the upside if its molecules succeed. The investment picture is a classic pre-profit biotech setup: modest and lumpy platform revenue, sizeable R&D-driven net losses, and a large balance sheet (roughly $531M in cash and marketable securities plus additional non-dilutive government funding) meant to fund the pipeline for years. The story now rides on two lead assets, ABCL-635 for menopausal vasomotor symptoms and ABCL-575 for atopic dermatitis, both with top-line data expected in 2026. That makes the stock highly catalyst-sensitive: strong readouts could re-rate it, while disappointments would leave a company valued well above its trailing fundamentals.
What's the case for buying ABCL?
1. Own-pipeline catalysts in 2026
AbCellera has two internal candidates in the clinic with near-term readouts: ABCL-635 (a potential first-in-class NK3R antibody for menopausal hot flashes) with top-line Phase 2 data guided to Q3 2026, and ABCL-575 for atopic dermatitis with Phase 1 top-line data expected in Q4 2026. Positive interim Phase 1 ABCL-635 data showed a clean safety profile and an ~24-day half-life supporting once-monthly dosing. These readouts are the dominant value drivers for the year.
2. Deep cash runway
The company ended Q1 2026 with about $531M in cash and marketable securities and roughly $655M in total available liquidity including non-dilutive government funding. That balance sheet lets it push multiple programs through the clinic without immediate reliance on dilutive raises, a meaningful advantage for a pre-revenue-scale biotech.
3. Platform and royalty optionality
AbCellera has completed over 100 antibody-discovery programs and retains downstream milestone and royalty rights across many partner programs, plus blue-chip relationships (Eli Lilly, Regeneron, AbbVie, Biogen). Any partner-program approvals could add royalty streams on top of the internal pipeline, giving a second, lower-cost source of potential upside.
4. Expanding earlier-stage pipeline
Beyond the two clinical assets, AbCellera is advancing ABCL-688 and ABCL-386 through IND-enabling work with a target of entering clinical trials by 2027, and aims to add new development candidates. This widening internal pipeline is how management intends to build a durable, multi-shot-on-goal drug portfolio rather than a single-asset bet.
What are the risks to ABCL?
AbCellera is unprofitable and burning cash, posting a net loss of roughly $43M in Q1 2026 against only about $8M of quarterly revenue, so the market value rests on future clinical success rather than current earnings. Its stock is highly binary: a miss on the ABCL-635 or ABCL-575 readouts could sharply reset the valuation. Platform revenue has fallen far from its pandemic-era peak (when Lilly antibody royalties were large) and is lumpy and partner-dependent. Drug development carries the usual risks of trial failure, regulatory delay and competition in crowded indications, and while the cash runway is long, sustained losses could eventually require dilutive financing.
How is ABCL valued? (as of JULY 2026)
Snapshot for ABCL as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Market cap: ~$2.4B
- Share price: ~$7.70
- Revenue (Q1 2026): ~$8.3M (up from ~$4.2M yr-ago)
- Net loss (Q1 2026): ~$43M
- Cash & marketable securities: ~$531M
- Total available liquidity: ~$655M
AbCellera has no P/E because it is unprofitable, so investors typically frame it on cash-versus-market-cap and pipeline optionality: a large portion of the roughly $2.4B market value is backed by its cash and liquidity, with the remainder pricing the pipeline. Revenue is small and lumpy relative to the market cap, which is normal for a clinical-stage biotech but means the shares trade on catalysts, not fundamentals. Analyst views vary; for example Benchmark upgraded the stock to Buy with an $11 target, reflecting how much depends on the 2026 readouts.
How do you decide if ABCL is a buy?
Rather than asking whether ABCL is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ABCL indirectly through an index or sector ETF before adding more.
For the full picture, see the ABCL stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ABCL against your real portfolio and see your actual exposure before deciding.
The bottom line on ABCL
The bottom line: AbCellera Biologics's story right now is Own-pipeline catalysts in 2026, with revenue (q1 2026) at ~$8.3M (up from ~$4.2M yr-ago). If you believe that narrative continues, the call is about sizing ABCL sensibly and checking overlap with what you own; if you doubt it (the risk: abCellera is unprofitable and burning cash, posting a net loss of roughly $43M in Q1 2026 against only about $8M of quarterly revenue, so the market value rests on future clinical success rather than current earnings.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ABCL with Walnut
Use AbCellera Biologics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ABCL a good stock to buy right now?
+
The case for AbCellera Biologics right now is Own-pipeline catalysts in 2026, with revenue (q1 2026) at ~$8.3M (up from ~$4.2M yr-ago). If you believe that thesis holds, ABCL is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is abCellera is unprofitable and burning cash, posting a net loss of roughly $43M in Q1 2026 against only about $8M of quarterly revenue, so the market value rests on future clinical success rather than current earnings. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does AbCellera Biologics do?
+
AbCellera Biologics (Nasdaq: ABCL) built an AI-assisted, single-cell antibody-discovery platform (spun out of the University of British Columbia) that it originally rented to pharm
What are the main risks of ABCL?
+
AbCellera is unprofitable and burning cash, posting a net loss of roughly $43M in Q1 2026 against only about $8M of quarterly revenue, so the market value rests on future clinical success rather than current earnings. Its stock is highly binary: a miss on the ABCL-635 or ABCL-575 readouts could sharply reset the valuation. Platform revenue has fallen far from its pandemic-era peak (when Lilly antibody royalties were large) and is lumpy and partner-dependent. Drug development carries the usual risks of trial failure, regulatory delay and competition in crowded indications, and while the cash runway is long, sustained losses could eventually require dilutive financing.
What does AbCellera Biologics do?
+
AbCellera uses an AI-assisted, single-cell antibody-discovery platform to find therapeutic antibodies. It historically partnered with drugmakers for fees and royalties and is now developing its own antibody drugs in-house, shifting from a services model toward being a clinical-stage developer.
Is AbCellera profitable?
+
No. AbCellera is a pre-profit biotech that posted a net loss of about $43M in Q1 2026 on roughly $8M of revenue. Like most clinical-stage companies, it spends heavily on R&D and funds itself from a large cash balance rather than operating profit.
How much cash does AbCellera have?
+
As of Q1 2026 the company reported about $531M in cash and marketable securities, and roughly $655M in total available liquidity including non-dilutive government funding. That gives it a multi-year runway to advance its pipeline.
What are AbCellera's lead drug candidates?
+
Its two clinical assets are ABCL-635, an antibody for menopausal vasomotor symptoms (hot flashes) with Phase 2 top-line data expected in Q3 2026, and ABCL-575 for atopic dermatitis with Phase 1 top-line data expected in Q4 2026. ABCL-688 and ABCL-386 are earlier-stage.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ABCL; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.